Holen Sie sich die Stockscreener-App
0.8045
4.49%
0.0346
Schlusskurs vom Vortag:
$0.7699
Offen:
$0.75
24-Stunden-Volumen:
162.42K
Relative Volume:
0.56
Marktkapitalisierung:
$18.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.43M
KGV:
-0.2255
EPS:
-3.5677
Netto-Cashflow:
$-15.21M
1W Leistung:
+12.52%
1M Leistung:
+1.00%
6M Leistung:
-2.19%
1J Leistung:
-36.65%
1-Tages-Spanne:
$0.7412
$0.82
1-Wochen-Bereich:
$0.5397
$0.82
52-Wochen-Spanne:
$0.281
$3.79
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Firmenname
Pasithea Therapeutics Corp
Sektor
Branche
Telefon
(702) 514-4174
Adresse
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.8028 | 17.78M | 0 | -20.43M | -15.21M | -3.5677 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
Pasithea Therapeutics Corp reports results for the quarter ended December 31Earnings Summary - TradingView
KTTA Should I Buy - Intellectia AI
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity - Sahm
Trade Report: Is Pasithea Therapeutics Corp stock influenced by commodity prices2026 Biggest Moves & Technical Entry and Exit Tips - baoquankhu1.vn
Pasithea receives FDA fast track status for NF1 drug candidate By Investing.com - Investing.com Australia
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity - Investing News Network
Pasithea receives FDA fast track status for NF1 drug candidate - Investing.com
KTTA SEC FilingsPasithea Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Signal Recap: Whats the beta of Pasithea Therapeutics Corp stockDividend Hike & Verified Entry Point Detection - baoquankhu1.vn
Pasithea (NASDAQ: KTTA) highlights PAS-004 trials and NF1 focus - Stock Titan
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Reviewing Pasithea Therapeutics (NASDAQ:KTTA) and Forte Biosciences (NASDAQ:FBRX) - Defense World
Can Pasithea Therapeutics Corp disrupt its industryMarket Trend Review & High Return Stock Watch Alerts - baoquankhu1.vn
Highs Report: What is the long term forecast for Pasithea Therapeutics Corp stockQuarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Can Pasithea Therapeutics Corp sustain earnings growth2026 Chart Watch & High Yield Stock Recommendations - baoquankhu1.vn
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock - simplywall.st
Winners Losers: Is Pasithea Therapeutics Corp Equity Warrant stock overvalued or fairly priced2026 Market Sentiment & Community Consensus Stock Picks - baoquankhu1.vn
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Panic Selling: Whats the beta of Pasithea Therapeutics Corp Equity Warrant stockGDP Growth & Weekly High Momentum Picks - baoquankhu1.vn
Pasithea Therapeutics Corp expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Layoff Watch: What is the next catalyst for Pasithea Therapeutics Corp Equity WarrantQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Gains Report: Is Pasithea Therapeutics Corp Equity Warrant attractive for institutional investors2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Analyst Calls: How does Pasithea Therapeutics Corp correlate with Nasdaq2026 Momentum & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Aug EndMonth: What is Pasithea Therapeutics Corp Equity Warrants revenue forecast2026 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
Smart Money: Whats the beta of Pasithea Therapeutics Corp stock2026 Historical Comparison & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Pullback Watch: Is Pasithea Therapeutics Corp Equity Warrant stock overvalued or fairly priced2026 Price Action Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Fund Flows: Is Pasithea Therapeutics Corp Equity Warrant impacted by rising rates2026 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
Will Pasithea Therapeutics Corp. Equity Warrant stock recover faster than market2026 Patterns & Entry Point Strategy Guides - Naître et grandir
RSI Check: What is Pasithea Therapeutics Corp Equity Warrants revenue forecastJuly 2025 Rallies & Expert Approved Momentum Ideas - baoquankhu1.vn
Earnings Recap: Whats the beta of Pasithea Therapeutics Corp stockMarket Risk Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Fed Watch: Whats the beta of Pasithea Therapeutics Corp Equity Warrant stockIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn
Certain Options of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026. - marketscreener.com
Certain Common Stock of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026. - marketscreener.com
KTTA PE Ratio & Valuation, Is KTTA Overvalued - Intellectia AI
KTTA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Coastlands entities hold 2.39M shares in Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
KTTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
What’s next for Pasithea Therapeutics Corp. stockTrade Entry Report & AI Enhanced Execution Alerts - mfd.ru
Pasithea Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CVI and Heights disclose 3.8% Pasithea (KTTA) stake via warrant holdings - Stock Titan
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Investing News Network
Pasithea Therapeutics Corp. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 - Quiver Quantitative
NF1-PN drug developer Pasithea to present at Oppenheimer event - Stock Titan
Can Pasithea Therapeutics Corp. disrupt its industryQuarterly Market Summary & Daily Stock Trend Reports - mfd.ru
Published on: 2026-02-12 18:27:19 - mfd.ru
Aug Mood: How does Pasithea Therapeutics Corp. correlate with NasdaqJuly 2025 Setups & Smart Investment Allocation Tips - mfd.ru
Published on: 2026-02-12 00:18:47 - mfd.ru
Why Pasithea Therapeutics Corp. stock is seen as undervaluedTrade Analysis Summary & AI Forecast for Swing Trade Picks - mfd.ru
What’s the beta of Pasithea Therapeutics Corp. stockWeekly Trading Summary & Precise Buy Zone Identification - mfd.ru
Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pasithea Therapeutics Corp-Aktie (KTTA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):